Figure 2
Figure 2. CMV-specific immune reconstitution after T-cell infusion. ELISPOT (A,B) and tetramer (C) analysis of response to CMV-pp65 (▴), CMV-IE1 (■), and adenoviral-hexon protein (•) in the trial participants over 3 months after T-cell infusion. Total white cell count (♦) and CMV PCR titer (×) are also shown. Presence of GVHD and corticosteroids is indicated by striped and spotted bars, respectively. Note the individual variation in scale of the y-axis. (A) Five participants with predominantly pp65 immune reconstitution. (B) Three participants with IE1 immune reconstitution matching that of pp65 (2 left panels) or dominating the response (right panel). (C) CMV-pp65 epitope-specific immune reconstitution over 3 months after T-cell infusion as assessed by tetramer binding in 5 patients. Total white cell count (×106/mL) is represented by ♦; tetramer+ cell count (×104/mL) is shown as ▴. CMV PCR titer (×102 copies/mL) is represented by ×. The HLA restriction of the tetramers used included HLA A*0201 (06 205 and 07 169), HLA B*0702 (0702 and 07 143), and HLA B*0801 (0786).

CMV-specific immune reconstitution after T-cell infusion. ELISPOT (A,B) and tetramer (C) analysis of response to CMV-pp65 (▴), CMV-IE1 (■), and adenoviral-hexon protein (•) in the trial participants over 3 months after T-cell infusion. Total white cell count (♦) and CMV PCR titer (×) are also shown. Presence of GVHD and corticosteroids is indicated by striped and spotted bars, respectively. Note the individual variation in scale of the y-axis. (A) Five participants with predominantly pp65 immune reconstitution. (B) Three participants with IE1 immune reconstitution matching that of pp65 (2 left panels) or dominating the response (right panel). (C) CMV-pp65 epitope-specific immune reconstitution over 3 months after T-cell infusion as assessed by tetramer binding in 5 patients. Total white cell count (×106/mL) is represented by ♦; tetramer+ cell count (×104/mL) is shown as ▴. CMV PCR titer (×102 copies/mL) is represented by ×. The HLA restriction of the tetramers used included HLA A*0201 (06 205 and 07 169), HLA B*0702 (0702 and 07 143), and HLA B*0801 (0786).

Close Modal

or Create an Account

Close Modal
Close Modal